NASDAQ:GLMD Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.71 -0.03 (-4.05%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.71▼$0.7750-Day Range$0.29▼$0.9052-Week Range$0.29▼$1.84Volume161,489 shsAverage Volume125,795 shsMarket Capitalization$17.81 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Galmed Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside604.2% Upside$5.00 Price TargetShort InterestHealthy0.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.73) to ($0.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector687th out of 1,029 stocksPharmaceutical Preparations Industry347th out of 501 stocks 3.0 Analyst's Opinion Consensus RatingGalmed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Galmed Pharmaceuticals has a forecasted upside of 604.2% from its current price of $0.71.Amount of Analyst CoverageGalmed Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.66% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently decreased by 2.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLMD. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Galmed Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest12 people have searched for GLMD on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.30% of the stock of Galmed Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Galmed Pharmaceuticals are expected to grow in the coming year, from ($0.73) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Galmed Pharmaceuticals (NASDAQ:GLMD) StockGalmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.Read More Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.comFebruary 2, 2023 | americanbankingnews.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Receives Average Recommendation of "Hold" from AnalystsFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 25, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.comJanuary 6, 2023 | finance.yahoo.comCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?January 4, 2023 | marketwatch.comGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol StudyJanuary 4, 2023 | finance.yahoo.comGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholDecember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.September 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the UpgradeAugust 4, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 7, 2022 | finance.yahoo.comGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal ModelJuly 7, 2022 | nasdaq.comGalmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional IndicationsJuly 7, 2022 | finance.yahoo.comGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis ModelJune 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 25, 2022 | benzinga.comGalmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, PredictionsMay 18, 2022 | seekingalpha.comGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystMay 17, 2022 | finance.yahoo.comGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effectsMay 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2022 Financial ResultsMay 3, 2022 | marketwatch.comGalmed Pharmaceuticals Shares Down 16%May 3, 2022 | markets.businessinsider.comRaymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To KnowMay 2, 2022 | seekingalpha.comGalmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call TranscriptMay 2, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial ResultsApril 29, 2022 | benzinga.comGalmed Pharmaceuticals's Earnings OutlookApril 28, 2022 | finance.yahoo.comGalmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessmentApril 26, 2022 | finance.yahoo.comGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2January 11, 2022 | seekingalpha.comGalmed gains 5% after securing three new U.S. patents for Aramchol and meglumine saltSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Company Calendar Last Earnings11/16/2022Today2/04/2023Next Earnings (Estimated)5/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+604.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.97% Return on Assets-80.42% Debt Debt-to-Equity Ratio0.01 Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.58Miscellaneous Outstanding Shares25,090,000Free Float20,121,000Market Cap$17.81 million OptionableOptionable Beta1.18 Key ExecutivesAllen BaharaffChairman, President & Chief Executive OfficerGuy NehemyaChief Operating & Data Protection OfficerDoron CohenChief Financial OfficerLiat HayardenyChief Scientific OfficerNeta TobisDirector-Clinical AffairsKey CompetitorsAlterity TherapeuticsNASDAQ:ATHENanoViricidesNYSE:NNVCAcelRx PharmaceuticalsNASDAQ:ACRXGraybug VisionNASDAQ:GRAYContext TherapeuticsNASDAQ:CNTXView All Competitors GLMD Stock - Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares. View GLMD analyst ratings or view top-rated stocks. What is Galmed Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued twelve-month target prices for Galmed Pharmaceuticals' stock. Their GLMD share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 604.2% from the stock's current price. View analysts price targets for GLMD or view top-rated stocks among Wall Street analysts. How have GLMD shares performed in 2023? Galmed Pharmaceuticals' stock was trading at $0.50 at the beginning of 2023. Since then, GLMD stock has increased by 42.0% and is now trading at $0.71. View the best growth stocks for 2023 here. When is Galmed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our GLMD earnings forecast. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Wednesday, November, 16th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $0.71. How much money does Galmed Pharmaceuticals make? Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $17.81 million. The biopharmaceutical company earns $-32,470,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447. This page (NASDAQ:GLMD) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.